论文部分内容阅读
[目的]探索AFP和PIVKA-Ⅱ对PHC诊断的临床运用。[方法]收集原发性肝细胞癌87例、肝硬化39例、慢性肝病39例和体检健康对照25例的病例资料,对各组检测血清AFP和PIVKA-Ⅱ水平。[结果 ]与健康对照组相比,各肝病组AFP和PIVKA-Ⅱ均有不同程度升高(P<0.01);PHC组AFP和PIVKA-Ⅱ水平高于慢性肝病组和肝硬化组(P<0.01)。AFP和PIVKA-Ⅱ在辅助诊断PHC的敏感度和特异性分别为72%、68%和79%、62%;两者联合诊断时敏感度和特异性分别为91%和85%。[结论]AFP和PIVKA-Ⅱ联合诊断时可以进一步提高诊断的敏感度或特异性。
[Objective] To explore the clinical application of AFP and PIVKA-Ⅱ in the diagnosis of PHC. [Methods] The data of 87 cases of primary hepatocellular carcinoma, 39 cases of cirrhosis, 39 cases of chronic liver disease and 25 cases of healthy control were collected. Serum levels of AFP and PIVKA-Ⅱ were detected in each group. [Results] Compared with the healthy control group, AFP and PIVKA-Ⅱ in each liver disease group increased to some extent (P <0.01); AFP and PIVKA-Ⅱ in PHC group were higher than those in chronic liver disease group and cirrhosis group (P < 0.01). The sensitivity and specificity of AFP and PIVKA-Ⅱ in the diagnosis of PHC were 72%, 68% and 79%, 62% respectively. The diagnostic sensitivity and specificity of AFP and PIVKA-Ⅱ were 91% and 85% respectively. [Conclusion] The combined diagnosis of AFP and PIVKA-Ⅱ can further improve the sensitivity or specificity of diagnosis.